Lubei Chemical: A wholly-owned subsidiary plans to increase its capital in Mengda Titanium Industry to obtain 10% of its equity

On the evening of November 22, Lubei Chemical (600727) announced that its wholly-owned subsidiary, Shandong Xianghai Titanium Resources Technology Co., Ltd., signed a "Capital Increase Agreement" with Inner Mongolia Yuxiao Mengda Titanium Industry Co., Ltd. and its shareholders. Xianghai Technology plans to increase the capital of Mengda Titanium Industry with its own funds of 33.6444 million yuan. After the completion of the capital increase, Xianghai Technology will hold 10% of the equity of Mengda Titanium Industry.

According to the data, Lubei Chemical was established in June 1996, and its main business is titanium dioxide business, methane chloride business, fertilizer business, cement business, and salt business.

KPC: Approved to conduct clinical trials of KPC000154 tablets of a novel NASH treatment drug

On the evening of November 22, KPC (600422) announced that the new drug KPC000154 tablets jointly developed by the company and its wholly-owned subsidiary, KPC (Zhuhai Hengqin) Technology Co., Ltd., had obtained the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration. It means that KPC000154 tablets, as a new class 1 chemical drug, will officially enter the clinical trial stage. KPC000154 tablets are designed to treat nonalcoholic steatohepatitis (NASH).

According to the data, KPC was established in December 1995 and is mainly engaged in drug research and development, production and sales, pharmaceutical distribution and health industry.

MeCan Biotech: Obtained two in vitro diagnostic reagent medical device registration certificates

On the evening of November 22, MeCan Biotechnology (300439) announced that the company recently successfully obtained two "Medical Device Registration Certificates of the People's Republic of China (In Vitro Diagnostic Reagents)" issued by the Zhejiang Provincial Drug Administration.

According to the announcement, the products involved in the two registration certificates obtained by MeCan Biotech are: (1) β-Human chorionic gonadotropin detection kit (chemiluminescence microparticle immunoassay) is clinically used for early pregnancy diagnosis and pregnancy monitoring, and assessment of the risk of Down syndrome in the second trimester, and is not used for auxiliary diagnosis of tumors. (2) Homocysteine detection kit (latex enhanced immunoturbidimetry) for the quantitative determination of homocysteine (Hcy) concentration in human serum or plasma in vitro.

According to the data, MeCan Biotech was established in July 2003 and is mainly engaged in the research and development, production and sales of in vitro diagnostic products and the agency business of in vitro diagnostic products, and provides third-party medical diagnosis services.

Yuexiu Capital: The holding subsidiary plans to issue an asset-backed special plan of 720 million yuan

On the evening of November 22, Yuexiu Capital (000987) announced that its subsidiary, Guangzhou Yuexiu New Energy Investment Co., Ltd., plans to issue a special plan (quasi-REITs) for new energy infrastructure assets on the Shenzhen Stock Exchange, with an issuance scale of no more than 720 million yuan.

According to the data, Yuexiu Capital was established in December 1992, and its main business includes non-performing asset management, financial leasing, private equity fund management and capital investment.

Xiangjia shares in the first three quarters of the profit distribution plan: 10 distributions of 2 yuan

On the evening of November 22, Xiangjia shares (002982) disclosed the profit distribution plan for the first three quarters, and planned to distribute a cash dividend of 2 yuan (tax included) to all shareholders for every 10 shares. The distribution does not involve bonus shares or the conversion of provident fund into share capital.

According to the data, Xiangjia Co., Ltd. was established in April 2003, and its main business is poultry breeding, poultry breeding and sales, poultry slaughtering, processing and sales, feed and biofertilizer production and sales.

Donghua Technology: Signed an EPC general contracting contract for a 1.452 billion yuan synthetic green ammonia project

On the evening of November 22, Donghua Technology (002140) announced that the company had officially signed the EPC general contracting contract for the hydrogen production project and the synthetic ammonia project of the integrated wind and solar hydrogen production of the Shenzhen Energy Etuoke Banner, with a total contract amount of 1.452 billion yuan.

According to the data, Donghua Technology was established in July 2001, and its main business is to provide comprehensive services for the whole process and the whole industry chain such as consulting, design, construction and general contracting for the construction of domestic and foreign engineering projects.

China Unicom: As of October, the total number of "big connection" users reached 1.118 billionhouseholds

On the evening of November 22, China Unicom (600050) announced that by the end of October 2024, China Unicom's "big connection" users had reached 1.118 billion, including 288 million 5G package users and 606 million Internet of Things terminal connections.

According to the data, China Unicom was established in December 2001, and its main business is to provide integrated telecommunications services in China.

China Super Holdings: Won the bid for a number of national power grid projects with a total amount of 442 million yuan

On the evening of November 22, Zhongchao Holdings (002471) announced that the company and its wholly-owned subsidiaries Wuxi Mingzhu Cable Co., Ltd. (Mingzhu Cable), Jiangsu Yuanfang Cable Factory Co., Ltd. (Yuanfang Cable), Jiangsu Changfeng Cable Co., Ltd. (Changfeng Cable) and its holding subsidiary Jiangsu Zhongchao Cable Co., Ltd. (Zhongchao Cable) successfully won the bid for a number of national power grid projects, involving power cables, cloth wires, cluster insulated wires, control cables and other equipment, materials and goods.

According to the announcement, the total amount of winning bids reached 442 million yuan, accounting for 7.24% of the company's audited operating income in 2023.

According to the data, Zhongchao Holdings was established in July 1998, and its main business is garden engineering construction, landscape planning and design, greening maintenance, seedling production and marketing, water conservancy and hydropower projects.

Lingnan shares: The vice president of the company resigned

On the evening of November 22, Lingnan Co., Ltd. (002717) announced that Luo Lin had resigned as vice president of the company due to the company's strategic adjustment. According to the announcement, Luo Lin will no longer hold any position in the company and its subsidiaries after his resignation.

According to the data, Lingnan Co., Ltd. was established in July 1998, and its main business is garden engineering construction, landscape planning and design, greening maintenance, seedling production and marketing, water conservancy and hydropower projects.

Weining Health: Obtained three new invention patents

On the evening of November 22, Weining Health (300253) announced that the company had recently obtained three new invention patent certificates issued by the State Intellectual Property Office. These patents cover key technology areas such as image detection, medical data processing, and medical text generation. The acquisition of these invention patents will not have a significant impact on the company's operation in the short term.

According to the data, Weining Health was established in April 2004, and its main business is the research and development, sales and technical services of application software in the field of medical and health care.

Betta Pharmaceutical: The ensartinib hydrochloride capsule clinical center passed the on-site inspection of the US FDA

On the evening of November 22, Betta Pharmaceuticals (300558) announced that the ensartinib hydrochloride capsule (trade name: Bemena ®, referred to as "ensartinib") developed by its holding subsidiary Xcovery Holdings, Inc. is for the first-line treatment indication of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). It has successfully passed the U.S. Food and Drug Administration's (FDA) clinical BIMO (biological research monitoring) and related PAI (pre-approval inspection) on-site inspections.

According to the data, Betta Pharmaceuticals was established in January 2003, and its main business is the production and sales of innovative drugs.

Tonghe Pharmaceutical: Obtained the drug registration certificate of rivaroxaban tablets

On the evening of November 22, Tonghe Pharmaceutical (300636) announced that the company had obtained the "Drug Registration Certificate" for rivaroxaban tablets from the State Drug Administration. The approved rivaroxaban tablets include 10mg, 15mg and 20mg, which belong to category 4 chemical drugs and are suitable for the prevention and treatment of thrombotic events in adults and children.

According to the data, Tonghe Pharmaceutical Co., Ltd. was established in April 2004, and its main business is the research and development, production and sales of chemical raw materials and pharmaceutical intermediates.

Tasly: Suspension of clinical trials of ammelumab and provision for impairment

On the evening of November 22, Tasly (600535) announced that the recombinant fully human anti-EGFR monoclonal antibody injection (amelimumab) developed by Shanghai Saiyuan Biotechnology Co., Ltd., a holding subsidiary of Tasly Biopharmaceutical Co., Ltd., decided to suspend the clinical trial of the drug and make full asset impairment provision for the balance of the project's development expenditure due to the failure of the interim analysis results of the phase IIb clinical study to meet expectations.

According to the data, Tasly was established in April 1998, and its main business is the research and development, production and sales of drugs.

Jiuzhou Pharmaceutical: The holding subsidiary obtained the drug registration certificate of venlafaxine hydrochloride sustained-release capsules

On the evening of November 22, Jiuzhou Pharmaceutical (603456) announced that its holding subsidiary, Zhejiang Jiuzhou Biopharmaceutical Co., Ltd., successfully obtained the "Drug Registration Certificate" of venlafaxine hydrochloride sustained-release capsules issued by the State Drug Administration.

Venlafaxine hydrochloride extended-release capsules are mainly used for the treatment of depression (including depression with anxiety) and generalized anxiety disorder.

According to the data, Jiuzhou Pharmaceutical Co., Ltd. was established in July 1998, and its main business is pharmaceutical customized R&D and production (CDMO) services, including small molecule chemical drugs, peptide drugs, conjugate drugs and small nucleic acid drugs.

COSCO SHIPPING Energy: Signed a contract for the construction of six 307,000 dwt ultra-large oil tankers

On the evening of November 22, COSCO Shipping Energy (600026) announced that its wholly-owned subsidiary, Hainan COSCO Shipping Energy Transportation Co., Ltd., signed a contract with Dalian Shipbuilding Industry Group Co., Ltd. and China Shipbuilding Industry Trading Co., Ltd. for the construction of six 307,000-dwt VLCCs (ultra-large oil tankers).

According to the contract, the construction price of each VLCC is 958 million yuan, and the total price of a total of 6 ships is 5.748 billion yuan.

According to the data, COSCO SHIPPING Energy was established in July 1996, and its main business includes international and Chinese coastal crude oil and refined oil transportation, as well as international liquefied natural gas transportation.

Taienkang: A wholly-owned subsidiary, compound sodium sulfate tablets, was accepted for drug registration

On the evening of November 22, Taienkang (301263) announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., received the "Notice of Acceptance" for the registration and marketing authorization application for the domestic production of compound sodium sulfate tablets issued by the State Drug Administration.

Compound sodium sulfate tablets are a new type of oral solid tablet intestinal cleanser, which is mainly used for bowel preparation before colonoscopy in adults.

According to the data, Taienkang was established in January 1999, and its main business is agency operation and R&D, production and sales of pharmaceutical products, medical devices, sanitary materials, and medical technical services and technology transfer.

Luen Mei Holdings' 2024 special dividend plan: 10 distributions of 1.2 yuan are proposed

On the evening of November 22, Luen Mei Holdings (600167) disclosed a special dividend plan for 2024, proposing to distribute cash dividends of 1.20 yuan to all shareholders for every 10 shares, and the total cash dividend is expected to be 267 million yuan.

According to the data, Luen Mei Holdings was established in January 1999, and its main business is comprehensive energy services based on clean heating and digital media advertising business for high-speed rail.

Huazhi Liquor Company's profit distribution plan for the first three quarters: 10 distributions of 8.09 yuan are proposed

On the evening of November 22, Huazhi Liquor Store (300755) disclosed the profit distribution plan for the first three quarters, planning to distribute a cash dividend of 8.09 yuan to all shareholders for every 10 shares, and the total cash dividend is expected to be 330 million yuan. The distribution does not involve bonus shares or the conversion of capital reserve into share capital.

According to the data, Huazhi Liquor Store was established in May 2005, and its main business is the sales of alcoholic products.

Fu'an Pharmaceutical: Bosheng Pharmaceutical, a subsidiary, was approved for the marketing application of chemical APIs

On the evening of November 22, Fu'an Pharmaceutical (300194) announced that its wholly-owned subsidiary, Fu'an Pharmaceutical Group Chongqing Bosheng Pharmaceutical Co., Ltd., received the approval notice of the marketing application for chemical raw materials issued by the State Drug Administration.

The approved chemical API is ceftorenpixilate, which is mainly suitable for the treatment of diseases such as respiratory, urinary tract, skin and soft tissue infections caused by sensitive bacteria.

According to the data, Fu'an Pharmaceutical was established in February 2004 and is mainly engaged in the research and development, production and sales of chemical drugs.

Lisheng Pharmaceutical: The marketing application of arginine perindopril API was approved

On the evening of November 22, Lisheng Pharmaceutical (002393) announced that the company's chemical API arginine perindopril has successfully passed the marketing application of the State Drug Administration and obtained the "Notice of Approval of the Marketing Application of Chemical APIs".

Arginine perindopril is an effective vasodilator, mainly used in tablet form, for the treatment of hypertension and congestive heart failure.

According to the data, Lisheng Pharmaceutical was established in June 1981, and its main business is the research and development, production and sales of pharmaceutical products.

Garden Bio: The subsidiary obtained the drug registration certificate of alendronate sodium tablets

On the evening of November 22, Garden Biology (300401) announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., successfully obtained the "Drug Registration Certificate" of "Alendronate Sodium Tablets" issued by the State Drug Administration.

Alendronate tablets are a medication used to treat osteoporosis in postmenopausal women and osteoporosis in men to increase bone mass.

According to the data, Garden Biology was established in December 2000, and its main business is the research and development, production and sales of vitamin D3 upstream and downstream series products and high-tech barrier preparation products in the field of cardiovascular, nervous system and other chronic diseases.

Huitai Medical: Newly obtained the medical device registration certificate

On the evening of November 22, Huitai Medical (688617) announced that its wholly-owned subsidiary, Hunan Epte Medical Device Co., Ltd., successfully obtained an important medical device registration certificate issued by the State Drug Administration.

The approved product, named "Peripheral Relievable Spring Coil", belongs to the third category of passive medical devices, which are mainly used in the treatment of peripheral vascular system, including tamponade of aneurysms, arteriovenous malformations and arteriovenous fistulas.

According to the data, Huitai Medical was established in June 2002, and its main business is the research and development, production and sales of cardiovascular interventional medical devices.

Luokai shares: plans to participate in the acquisition of 45% of the shares of Fuzhou Yili

On the evening of November 22, Luokai shares (603829) announced that the company plans to participate in the acquisition of 45% of the shares of Fuzhou Yili Electrical Equipment Co., Ltd. publicly listed and transferred by Fujian Rongneng Electric Industry Group Co., Ltd., with a reserve price of 86.323 million yuan.

If the transaction is successful, the proportion of Fuzhou Yili held by Luokai will increase from 10% to 55%, and Fuzhou Yili will become a holding subsidiary of Luokai and be included in the company's consolidated financial statements.

According to the data, Panjiang Co., Ltd. was established in September 2010, and its main business is the research and development, production and sales of medium and low voltage power distribution equipment and its key accessories represented by circuit breakers and ring main units.

Industry: power equipment - power grid equipment - power distribution equipment

Panjiang Co., Ltd.: Unit 1 was officially put into commercial operation

On the evening of November 22, Panjiang Co., Ltd. (688455) announced that Unit 1 of the Panjiang Puding 26×66 thousand kilowatt coal-fired power generation project invested and constructed by Panjiang Puding Power Generation Co., Ltd., a wholly-owned subsidiary, has been officially put into commercial operation.

Previously, Panjiang Co., Ltd. disclosed the news of the first grid-connected power generation of Unit 1 on October 1, 2024, and entered the stage of commissioning and 168 hours of continuous full-load trial operation. After rigorous testing and evaluation, the unit successfully passed the 168-hour continuous full-load test operation on November 22, 2024, marking its official entry into the commercial operation stage.

According to the data, Panjiang Co., Ltd. was established in October 1999 and is mainly engaged in coal mining, washing, processing and sales, as well as the production and sales of electricity.

Dongfang Cable: Invested in the establishment of a subsidiary in Hong Kong, China and a grandson company in the United Kingdom

On November 22, Orient Cable (603606) announced that the company plans to set up a wholly-owned subsidiary in Hong Kong, Hong Kong Orient International (HK) Ltd., and set up a grandson company wholly owned by the Hong Kong subsidiary in the United Kingdom - Orient Cable (NBO UK) Ltd. (Orient Cable (NBO UK) Ltd. The total investment is 7.5 million pounds (about 69 million yuan), which aims to deepen the company's global layout in the field of offshore wind power, especially in the UK market.

According to the data, Dongfang Cable was established in October 1998 and is mainly engaged in the research and development, manufacturing and sales of submarine cable systems and terrestrial cable system products, as well as marine engineering services.

Arctech: The total shareholding ratio of the actual controller is passively diluted to 40.88

On November 22, Arctech (688408) issued a reminder announcement on the change in the equity of controlling shareholders, actual controllers and persons acting in concert with them reaching 5%. According to the announcement, the change in equity is the result of multiple factors such as the company's controlling shareholder and the actual controller's concerted action to reduce the company's shares, and the company's issuance of shares to specific targets.

After this equity change, the total number of shares owned by Arctech's controlling shareholders, actual controllers and persons acting in concert with them is 89.335 million shares, accounting for 46.14% of the company's total share capital to 40.88%, and the total shareholding ratio is reduced by 5.26%.

According to the data, Arctech was established in November 2009, and its main business is a manufacturer and solution provider of photovoltaic tracking brackets, fixed brackets and BIPV systems.

Shuangyuan Technology: A total of 16.7139 million yuan of government subsidies have been obtained

On November 22, Shuangyuan Technology (688623) announced that from January 2024 to the date of the announcement, the company has received a total of 16.7139 million yuan in subsidies from the government. These grants are income-related government grants.

According to the data, Shuangyuan Technology was established in March 2006, and its main business is to provide enterprises with an online automatic measurement and control system for high-precision closed-loop control of process parameters such as areal density/thickness/gram weight/quantitative, moisture, ash and other process parameters in the production process of products.

Chinalco International: Zhao Hongmei, chief financial officer, resigned

On November 22, Chinalco International (601068) announced that Zhao Hongmei, the company's former chief financial officer, submitted a resignation application to the company's board of directors due to work adjustments, which will take effect from now on. Zhao Hongmei will no longer serve as the company's chief financial officer. The company decided to appoint Tao Fulun as the new chief financial officer, whose term of office will be from the date of deliberation and approval of the 25th meeting of the fourth board of directors until the end of the term of the fourth board of directors.

According to the data, Chinalco International was established in December 2003, and the company's business mainly includes engineering survey, design and consulting, engineering construction and contracting, and equipment manufacturing.

Valin Seiko: Director Li Zhengqiu resigned

On November 22, Valin Seiko (603356) announced that Li Zhengqiusheng, a non-independent director of the company, submitted a written resignation report to the company's board of directors for personal reasons, applying for resignation as a non-independent director of the fourth board of directors. After his resignation, Li Zhengqiu will no longer hold any position in the company.

According to the data, Valin Seiko was established in September 2005, mainly engaged in the research and development, production and sales of elevators, mechanical parking equipment, wind power and other accessories.

Shanghai Electric Co., Ltd.: It is planned to increase the capital of its holding subsidiary by way of debt-to-equity swap

On November 22, Shanghai Electric Co., Ltd. (002463) announced that based on the purpose of improving the financial structure of its holding subsidiary, Shengweice Electronics (Jiangsu) Co., Ltd. and reducing its financial interest burden, Shanghai Electric Co., Ltd. decided to increase its capital by 21.9715 million euros in the form of debt-to-equity swap.

After the completion of this capital increase, the registered capital of SVT will increase to 110 million euros, and the company's direct shareholding in SVT will increase from 80% to 84%. At the same time, the indirect shareholding of Szweizer through its related party, Schweizer Electronic AG., will be reduced from 3.9480% to 3.1584%. Despite this, SVT remains a holding subsidiary of the Company.

According to the data, Hudian Co., Ltd. was established in April 1992, and its main business is the production, sales and related after-sales service of printed circuit boards.

Fenghua shares: 51% of the shares of Xinyuan Agricultural Machinery were donated by the controlling shareholder free of charge

On November 22, Fenghua Co., Ltd. (600615) announced that the controlling shareholder Dongfang Xinyuan Group Co., Ltd. intends to donate 51% of the equity held by Chongqing Xinyuan Agricultural Machinery Co., Ltd. to Fenghua Co., Ltd. free of charge. This move aims to enhance the market competitiveness and profitability of Fenghua shares through resource integration.

According to the data, Fenghua Co., Ltd. was established in June 1992, and its main business is the production of magnesium alloy and aluminum alloy products.

Zhongda De: It is planned to purchase land use rights of no more than 30 million yuan

On November 22, Zhongda (002896) announced that the company plans to use no more than 30 million yuan of its own or self-raised funds to bid for the right to use industrial land in Cixi Smart Home Appliance High-tech Industrial Park through public bidding, auction or listing.

According to the data, Zhongda was established in November 2008 and is mainly engaged in providing data research/analysis integration services, related digital and intelligent application technology products and industry digital application solutions based on data analysis methodology and data intelligent analysis technology.

New industry: The company obtained the medical device registration certificate

On November 22, New Industry (300832) announced that the company had successfully obtained a "Medical Device Registration Certificate" issued by the Guangdong Provincial Drug Administration.

The product that obtained the registration certificate this time is called "cyclosporine assay kit (magnetic particle chemiluminescence method)", which belongs to Class II medical devices and is valid from November 15, 2024 to November 14, 2029. This kit is mainly used for the quantitative determination of cyclosporine (CsA) concentration in human whole blood samples in vitro, and is suitable for clinical monitoring of blood concentration of cyclosporine.

According to the data, Xinye was established in November 2008 and is mainly engaged in providing data research/analysis integration services, related digital and intelligent application technology products and industry digital application solutions based on data analysis methodology and data intelligent analysis technology.

Huichen shares: shareholders plan to reduce their holdings of no more than 3% of the company's shares

On November 22, Huichen shares (688500) announced that the shareholder Hainan Jinhuicong Venture Capital Co., Ltd. plans to reduce its holdings of no more than 2,228,200 shares of the company in the next three months through centralized bidding transactions and block transactions, that is, no more than 3.00% of the company's total share capital.

According to the data, Huichen Co., Ltd. was established in November 2008, and its main business is to provide data research/analysis integration services, related digital and intelligent application technology products and industry digital application solutions based on data analysis methodology and data intelligent analysis technology.

OCT A: The government department plans to acquire and store the land of the subsidiary's TOD project

On November 22, OCT A (000069) announced that its wholly-owned subsidiary, Wuhan Tianchuang Real Estate Co., Ltd., is located in Yangchun Lake High-speed Railway Business District, Hongshan District, Wuhan City, with a land of about 105.32 acres, and was originally planned to be built as a TOD project on top of the subway where high-end industries gather. The government plans to adjust the original construction index of commercial offices and residential buildings to residential buildings and commercial offices to supplement commercial offices through the methods of acquisition and storage, adjustment of planning and re-supply of land, and carry out open market bidding, auction and listing of the land after the adjustment. Tianchuang Company plans to participate in the land bidding after regulation through bidding, auction and listing. The TOD project has completed the planning adjustment demonstration and has met the conditions for regulation.

According to the data, OCT A was established in September 1997 and is mainly engaged in tourism business and real estate business.

Infront: Shareholders intend to reduce their holdings of no more than 3% of the company's shares

On November 22, Infront Micro (000670) announced that Orient Securities Co., Ltd., a shareholder holding more than 5% of the shares, plans to reduce its holdings of the company's shares through centralized bidding and block trading within 3 months after 15 trading days from the date of disclosure of the announcement, and the upper limit of the number of shares to be reduced does not exceed 3% of the company's total share capital.

According to the data, Infront Micro was established in February 1993, and its main business is the distribution of electronic components and the research and development, design and sales of integrated circuit chips.

Hengrun shares: transferred the equity of the grandson company and cancelled the wholly-owned subsidiary

On November 22, Hengrun Co., Ltd. (603985) announced that the company will acquire 100% of the equity of Guangdong Lanrun New Materials Co., Ltd. at a price of 25 million yuan from its wholly-owned subsidiary, Beijing Lanrun Technology Development Co., Ltd.

At the same time, Hengrun plans to liquidate and cancel the Jiaxing Guohe Zhiming Equity Investment Partnership (Limited Partnership) held by Beijing Lanrun. Beijing Lanrun's subscribed capital contribution in the State Nuclear Zhiming is 450 million yuan, but the actual capital contribution is only 1 million yuan. After the completion of the above-mentioned equity transfer and liquidation procedures, the company will officially cancel Beijing Lanrun.

The countermeasures planned by Nachuan include: increasing the recovery of accounts receivable. Communicate with banks and financial institutions to gradually solve the problem of overdue debts by extending loans and adjusting repayment plans. Increase the disposal of non-main business assets and improve the company's operating conditions.

According to the data, Hengrun Co., Ltd. was established in July 2003 and is mainly engaged in the research and development, production and sales of rolling ring forgings, forged flanges and other free forgings.

Nachuan shares: the company owes interest and the bank loan of the subsidiary is overdue

On November 22, Nachuan shares (300198) announced that due to the impact of multiple factors such as the long-term arrears of accounts receivable of PPP projects and BT projects invested by the company and the intensification of market competition, the company is currently facing serious liquidity problems, resulting in the failure to repay the principal of some bank loans and current loan interest on time, and there is a situation of overdue and arrears. According to the announcement, the total overdue amount of PPP project loans is 161 million yuan. The outstanding interest on current loans totaled 2.724 million yuan.

The countermeasures planned by Nachuan include: increasing the recovery of accounts receivable; Communicate with banks and financial institutions to gradually solve the problem of overdue debts by extending loans and adjusting repayment plans; Increase the disposal of non-main business assets and improve the company's operating conditions.

According to the data, Nachuan Co., Ltd. was established in June 2003, and its main business is R&D, manufacturing and sales of water supply and drainage pipes, pipeline repair, pipeline engineering services, pipeline network investment and operation business, and new energy vehicle business.

Huasen Pharmaceutical: Approval of marketing application for agomelatine chemical API

On November 22, Huasen Pharmaceutical (002907) announced that the company had obtained the approval notice of the marketing application of agomelatine chemical API issued by the National Medical Products Administration (NMPA).

The approved chemical API is called agomelatine, a new antidepressant drug that relieves depressive symptoms while adjusting patients' biological rhythms.

According to the data, Huasen Pharmaceutical was established in November 1996 and is mainly engaged in the research and development, production and sales of Chinese patent medicines and chemical drugs.

CNOOC: President Lu Tao resigned

On November 22, CNOOC (601808) announced that Lu Tao, president of the company, had formally submitted a written resignation application to the board of directors on November 20, 2024 due to personal work changes. According to the announcement, Lu Tao's resignation is effective immediately, and neither party has any differences of opinion on this resignation.

According to the data, CNOOC was established in December 2001, and its main business involves all stages of oil and gas exploration, development and production, which are mainly divided into four major sectors: drilling services, oilfield technical services, ship services and geophysical exploration services.

Nhwa Pharmaceutical: Obtained the drug registration certificate for micuronium chloride injection

On November 22, Nhwa Pharmaceutical (002262) announced that it had recently successfully obtained the "Drug Registration Certificate" issued by the State Drug Administration for the chemical drug micuronium chloride injection.

Mirezone chloride is mainly used as an adjunct in the process of general anesthesia, which can effectively relax skeletal muscles and facilitate endotracheal intubation and mechanical ventilation.

According to the data, Nhwa Pharmaceutical Co., Ltd. was established in March 1999, and its main business is pharmaceutical production, R&D and sales, including pharmaceutical sales and pharmaceutical wholesale and retail business.